Electrocardiographic and hemodynamic effects of cisapride alone and combined with erythromycin in anesthetized dogs

Cardiovascular Toxicology

Volumn 2, Issue 3, 2002, Pages 195-207

  Al Wabel, Naser A ^a   Strauch, S Mark ^a   Keene, Bruce W ^b   Nakayama, Tomohiro ^a   Hamlin, Robert L ^a,c  

^a OHIO STATE UNIVERSITY   (United States)

^b NORTH CAROLINA STATE UNIVERSITY   (United States)

^c NONE   (United States)

Author keywords

Cardiotoxicity; ECG; Programmed electrical stimulation; QTc; Torsades de pointes; Ventricular function

Indexed keywords

CHLORALOSE; CISAPRIDE; ERYTHROMYCIN; MORPHINE;

ANESTHESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA PRESSURE; ARTICLE; CARDIOTOXICITY; CARDIOVASCULAR SYSTEM; CONTROLLED STUDY; DRUG EFFECT; ELECTROCARDIOGRAM; ELECTROCARDIOGRAPHY; ELECTROSTIMULATION; FEMALE; HEART ARRHYTHMIA; HEART LEFT VENTRICLE CONTRACTILITY; HEART LEFT VENTRICLE PRESSURE; HEART RATE; HEART REPOLARIZATION; HEMODYNAMIC MONITORING; HEMODYNAMICS; LONG QT SYNDROME; MALE; NONHUMAN; PRIORITY JOURNAL; QT INTERVAL; STATISTICAL SIGNIFICANCE; T WAVE; ANIMAL; COMPARATIVE STUDY; DOG; DOSE RESPONSE; DRUG COMBINATION; DRUG POTENTIATION; INTRAVENOUS ANESTHESIA; INTRAVENOUS DRUG ADMINISTRATION; METHODOLOGY; PHYSIOLOGY;

ANIMALIA; CANIS FAMILIARIS;

ANESTHESIA, INTRAVENOUS; ANIMALS; CISAPRIDE; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; DRUG SYNERGISM; ELECTROCARDIOGRAPHY; ERYTHROMYCIN; FEMALE; HEMODYNAMIC PROCESSES; INJECTIONS, INTRAVENOUS; MALE;

EID: 0038506226     PISSN: 15307905     EISSN: None     Source Type: Journal    
DOI: 10.1385/CT:2:3:195     Document Type: Article

References (37)

1. CISAPRIDE (1995). In Veterinary Handbook. Pharma Vet Publishing, White Bear, MN, pp. 134-135.
2. Ahmed, S.R. (1995). Cisapride and torsades de pointes. The Lancet 345:508.
3. Dowling, P.M. (1995). Prokinetic drugs: metoclopramide and cisapride. Canad. Vet. J. 36:115-116.
4. Kuroda, T., Yoshihara, Y., Nakamura, H., et al. (1992). Effects of cisapride on gastrointestinal motor activity and gastric emptying of disopyramide. J. Pharmaco-Dyn. 15:395-402.
5. Neufang, T., Scharmek, P., Ludtke, F.E., and Lepsien, G. (1991). Cisapride effects on canine lower esophageal sphincter under various pharmacological pretreatments. Dig. Dis. 9:369-400.
6. Wiseman, L.R. and Faulds, D. (1994). Cisapride: An updated review of its pharmacology and therapeutic efficacy as a prokinetic agent in gastrointestinal motility disorders. Drugs 47:116-152.
7. Cisapride (1993). In US Pharmacopoeia, Systemic. pp. 2896-2898.
8. Michalets, E.L. (1998). Update: clinically significant cytochrome P-450 drug interactions. Pharmacotherapy 18:84-112.
9. Washabau, R.J. and Hall, J.A. (1995). Cisapride. JAVMA 207:1285-1288.
10. Rubart, M., Pressles, M.L., Pride, H.P., and Zipes, D.P. (1993). Electrophysiological mechanisms in a canine model of erythromycin-associated long QT syndrome. Circulation 88:1832-1844.
11. Tack, J., Coremans, G., and Janssens, J. (1995). A risk-benefit assessment of cisapride in the treatment of gastrointestinal disorders. Drug Safety 12:384-392.
12. Satoh, Y., Sugiyama, A., Kohji, T., and Hashimoto, K. (2000). Effects of mexiletine on the canine cardiovascular system complicating cisapride overdose: potential utility of mexiletine for the treatment of drug-induced long QT syndrome. Jpn. Pharmacol. 83:327-334.
13. Webster, R., Allan, G., Anto-Awuakye, K., et al. (2001). Pharmacokinetic/pharmacodynamic assessment of the effects of E4031, cisapride, terfenadine and terodiline on monophasic action potential duration in dog. Xenobiotica 31:633-650.
14. Sugiyama, A. and Hashimoto, K. (1998). Effects of gastrointestinal prokinetic agents, TKS159 and cisapride, on the in situ canine heart assessed by cardiohemodynamic and electrophysiological monitoring. Toxico. Appl. Pharmacol. 152:261-269.
15. Volmer, P.A. (1996). Cisapride toxicosis in dogs. Vet. Hum. Tox. 38:118-120.
16. Gibly, R.L., Walter, F.G., Kloster, J., Theodorou, A.A., and Osterloh, J. (1997). Cisapride poisoning. Vet. Hum. Tox. 39:231-233.
17. Bedford, T.A. and Rowbotham, D.J. (1996). Cisapride; drug interaction of clinical significance. Drug Safety 15:167-175.
18. Holzgrefe, H., Everitt, J., and Wright, E. (1987). Alpha-chloralose as a canine anesthetic. Lap. Anim. Scien. 37:587-595.
19. Tilley, L.P. (1992). Essentials of Canine and Feline Electrocardiogram: Interpretation and Treatment. 3rd ed., Lea & Febiger, Philadelphia, PA.
20. Michiels, M., Monbaliu, J., Hendriks, R., Geerts, R., Woestenborghs, R., and Heykants, J. (1987). Pharmacokinetics and tissue distribution of the new gastrokinetic agent cisapride in rat, rabbit, and dog. Arzneim.-Forsch./Drug Res. 37:1159-1167.
21. Bedu, A., Lupoglazoff, J.M., Faure, C., Denjoy, I., Casasoprana, A., and Aujard, Y. (1997). Cisapride high dosage and long QT interval. J. Pediatrics 130:164.
22. Bran, S., Murray, W.A., Hirsch, I.B., and Palmer, J.P. (1995). Long QT syndrome during high-dose cisapride. Arch. Intern. Med. 155:765-768.
23. Hanson, R., Browne, G., Fasher, B., Mcaskill, M., Morony, P., and Hawker, R. (1997). Cisapride-induced prolonged QT interval: too much of a good thing! J. Pediatrics 130:164-166.
24. Lewin, M.B., Bryant, R.M., Fenrich, A.L., and Grifka, R.G. (1996). Cisapride-induced long QT interval. J. Pediatrics 128:179-281.
25. Wysowski, D.K. and Bacsanyi, J. (1996). Cisapride and fatal arrhythmia. N. Engl. J. Med. 335:190-191.
26. Carlsson, L., Amos, G.J., Anderson, B., Drews, L., Duker, G., and Wadstedt, G. (1997). Electrophysiological characterization of prokinetic agents cisapride and mosapride in vivo and vitro: implications for proarrhythmic potential? J. Pharm. Exper. Therap. 282:220-227.
27. Puisieux, F.L., Adamantidis, M.M., Dumotier, B.M., and Dupuis, B.A. (1996). Cisapride-induced prolongation of cardiac action potential and early afterdepolarization in rabbit Purkinje fibers. Brit. J. Pharm. 117:1377-1379.
28. Douglas, W. (1985). Histamine and 5-hydroxytryptamine and their antagonists, in Goodman and Gilman's: The Pharmacological Basis of Therapeutics, 7th ed., pp. 604-638, Macmillan Publishing Company, New York.
29. Chen, Y., Lee, S., Hsieh, M., Hsiao, C., Yu, W., Chiou, C., and Chen, S. (1999). Effects of 17β-estradiol on tachycardia-induced changes of atrial refractoriness and cisapride-induced ventricular arrhythmia. J. Cardiovasc. Electrophysiol. 10:587-598.
30. Weissenburger, J., Nesterenko, V.V., Antzelevitch, C. (2000). Transmural heterogeneity of ventricular repolarization under baseline and long QT conditions in the canine heart in vivo: torsades de pointes develops with halothane but not pentobarbital anesthesia. J. Cardiovas. Electrophysiol. 11:290-304.
31. Sicouri, S., Fish, J., and Antzelevitch, C. (1994). Distribution of M cells in the canine ventricle. J. Cardiovas. Electrophysiol. 5:824-37.
32. Jones, D.L., Klein, G.J., Gulamhusein, S., and Jarvis, E. (1983). The repetitive ventricular response: relationship to ventricular fibrillation threshold in dogs. PACE 6:1258-1267.
33. McCallum, R.W., Prakash, C., Campoli-Richards, D.M., and Goa, K.L. (1988). Cisapride: a preliminary review of its pharmacodynamic and pharmacokinetics properties, and therapeutic use as a prokinetic agent in gastrointestinal motility disorders. Drugs 36:652-681.
34. Zimpfer, M., Sit, S., and Vatner, S. (1981). Effects of anesthesia on canine carotid chemoreceptor reflex. Circ. Res. 48:400-406.
35. Rath, D., Little, C., Zhang, H., et al. (1995). Sodium pentobarbital versus a-chloralose anesthesia: experimental production of substantially different slopes in the transmural CP/ATP ratio within the left ventricle of the canine myocardium. Circulation 91:471-475.
36. Cox, R. (1972). Influence of chloralose anesthesia on cardiovascular function in trained dogs. Am. J. Physiol. 223:660-667.
37. Berne, R. and Levy, M. (1998). The Cardiovascular System, in Physiology, 4th ed., pp. 382-383, Mosby, St. Louis, MO.